英文摘要 |
Purposes Hyperprolactinemia is a known adverse effect of antipsychotics, attributed to the blockade of dopamine D2 receptors in the posterior pituitary. While previous studies have shown the potential of add-on aripiprazole, a partial agonist of D2 receptors, to reduce atypical antipsychotic-induced hyperprolactinemia, this case report presents an instance where aripiprazole failed to alleviate amisulpride-induced hyperprolactinemia. Methods The case report describes a patient who developed mastitis attributed to hyperprolactinemia secondary to the use of antipsychotics, specifically amisulpride. The authors demonstrate the principles of using add-on aripiprazole to manage elevated prolactin levels. Furthermore, the article will discuss the reasons for the failure of aripiprazole to lower prolactin when combined with amisulpride from a pharmacological perspective. Results The difference in lipophilicity between amisulpride and aripiprazole is identified as a contributing factor to the varying affinities for dopamine D2 receptors in the pituitary. This pharmacological distinction elucidates the inability of aripiprazole to regulate amisulpride-induced hyperprolactinemia. Conclusions This case highlights the paramount importance for healthcare professionals to remain vigilant regarding the risk of mastitis resulting from antipsychotic side effects. Regular monitoring of blood prolactin levels is crucial for patients on amisulpiride, particularly men and menopausal women. Furthermore, adopting a multidisciplinary team approach is essential for managing uncommon infections. Early identification and intervention of elevated prolactin levels induced by amisulpiride play a pivotal role in preventing further side effects. |